-+ 0.00%
-+ 0.00%
-+ 0.00%

Orchestra BioMed Presents BACKBEAT Trial Update, Targets Primary Data in Q2 2027

PUBT·11/12/2026 15:50:11
Orchestra BioMed Presents BACKBEAT Trial Update, Targets Primary Data in Q2 2027
  • Orchestra BioMed surpassed its BACKBEAT pivotal trial enrollment target, randomizing 349 patients.
  • Primary endpoint data for AVIM Therapy are targeted for presentation at HRS in the second quarter of 2027.
  • Potential FDA approval and Medtronic commercial launch are targeted for the first half of 2028.
  • Current cash provides runway through 2028; strategic partners have invested or paid more than $185 million.
  • The Medtronic collaboration provides an uncapped, double-digit royalty-based revenue share on every AVIM Therapy-enabled device sold.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.